Tübingen, Germany-based mRNA firm CureVac has appointed Pierre Kemula as its new chief financial officer.
Kemula will have responsibility for managing CureVac’s financial and capital markets activities and joins the company’s management board.
Previously, Kemula served as chief financial officer of Pixium Vision, a medical technology company specialising in the development of technologies for patients with outer retinal degeneration.
He also brings experience from Ipsen, where he was vice president of corporate finance, treasury and financial markets, and from consulting firms Roland Berger, Kea & Partners, Gemini Consulting and KPMG.
Ingmar Hoerr, co-founder and chief executive officer of CureVac, said: “Adding an executive with Pierre’s financial and transactional expertise, as well as his global markets experience, is a key accomplishment for CureVac as the company prepares for multiple near-term corporate and clinical milestones that have the potential to significantly contribute to its leadership position in the field of mRNA.”